Special Issue

Feature Reviews in Cardiovascular Diseases

Message from the Guest Editors

Despite the progress made in the prevention and treatment of cardiovascular diseases, the number of hospital admissions, healthcare spending, and mortality from cardiovascular causes still rank first in developed and developing countries. However, it must be admitted that cardiovascular diseases are a branch of medicine in which the greatest progress is made every year. In light of these developments, we have proposed this Special Issue entitled "Feature Reviews in Cardiovascular Diseases". It aims to collect the newest and most significant data on cardiovascular research, both in the field of cardiovascular prevention and mechanisms and on the rapeutic innovations such as inhibitors of SGLT2 receptors and GLP1 receptor agonists, which have given positive results on adverse cardiovascular outcomes. even regardless of the presence of diabetes.

Guest Editors

Dr. Serafino Fazio

Department of Internal Medicine, School of Medicine, Federico II University, Via Sergio Pansini 5, 80135 Naples, Italy

Dr. Arturo Cesaro

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy

Deadline for manuscript submissions

closed (31 August 2025)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/213591

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).